Trump announces deals with Lilly, Novo Nordisk to lower obesity drug prices

President Donald Trump on Thursday announced deals with Eli Lilly (LLY) and Novo Nordisk (NVO) to reduce the prices of some of their obesity drugs, including upcoming pills. The agreements will lower prices of GLP-1 drugs on Medicare and Medicaid and offer the treatments directly to consumers at a discount on a website the Trump administration is launching in January 2026 called TrumpRx.gov. Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk will be $145 per month for everyone getting them through Medicare, Medicaid or TrumpRx, and starting doses of existing injections like Novo’s Wegovy and Lilly’s Zepbound will be $350 per month on TrumpRX, but will “trend down” to $245 per month over a two-year period. In afternoon trading, shares of Eli Lilly are up 1.5% to $939.90, while shares of Novo Nordisk are up 1.3% to $49.06.